Eli Lilly to buy gene therapy developer Prevail in deal valued at $1.04 billion

Synopsis

Lilly talked about it will catch Prevail for $22.50 per portion, which represents a top price of 80% to Monday’s closing designate. The deal furthermore choices a “contingent price moral” price $4 per portion in money, contingent upon certain milestones being executed.

U.S. drugmaker Eli Lilly and Co talked about on Tuesday it will steal Prevail Therapeutics Inc in a deal valued at $1.04 billion, to assemble bigger its presence in the profitable field of gene treatment.

Lilly talked about it will catch Prevail for $22.50 per portion, which represents a top price of 80% to Monday’s closing designate. The deal furthermore choices a “contingent price moral” price $4 per portion in money, contingent upon certain milestones being executed.